MedTrace Logo

F01 in the Treatment of Autoimmune Diseases

NCT06208280 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-01-17

No results posted yet for this study

Summary

This is a multicenter, open lable clinical study to evaluate the safety and tolerability of F01 in autoimmune diseases.

Conditions

Interventions

DRUG

After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.

Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated. Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)

Sponsors & Collaborators

  • Shanghai Simnova Biotechnology Co.,Ltd.

    collaborator INDUSTRY

  • RenJi Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-09
Primary Completion
2025-01-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06208280 on ClinicalTrials.gov